Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts
Authors:
- Anderson ClarkACAnderson Clark
- Franck AssayagFAFranck Assayag
- Sophie Chateau-JoubertSCSophie Chateau-Joubert
- Marie-France PouponMPMarie-France Poupon
- Jean-Luc ServelyJSJean-Luc Servely
- Jean-Jacques FontaineJFJean-Jacques Fontaine
- Xiaohong LiuXLXiaohong Liu
- Edward SpoonerESEdward Spooner
- Samantha GoodstalSGSamantha Goodstal
- Patricia de CremouxPCPatricia de Cremoux
- Ivan BiècheIBIvan Bièche
Open Access
- 1 December 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 11 (12) , 2693-2703
Abstract
Triple-negative breast cancers (TNBC) have an aggressive phenotype with a relatively high rate of recurrence and poor overall survival. To date, there is no approved targeted therapy for TNBCs. Aurora kinases act as regulators of mammalian cell division. They are important for cell-cycle progression and are frequently overexpressed or mutated in human tumors, including breast cancer. In this study, we investigated the therapeutic potential of targeting Aurora kinases in preclinical models of human breast cancers using a pan-inhibitor of Aurora kinases, AS703569. In vitro, AS703569 was tested in 15 human breast cancer cell lines. TNBC cell lines were more sensitive to AS703569 than were other types of breast cancer cells. Inhibition of proliferation was associated with cell-cycle arrest, aneuploidy, and apoptosis. In vivo, AS703569 administered alone significantly inhibited tumor growth in seven of 11 patient-derived breast cancer xenografts. Treatment with AS703569 was associated with a decrease of phospho-histone H3 expression. Finally, AS703569 combined to doxorubicin–cyclophosphamide significantly inhibited in vivo tumor recurrence, suggesting that Aurora kinase inhibitors could be used both in monotherapy and in combination settings. In conclusion, these data indicate that targeting Aurora kinases could represent a new effective approach for TNBC treatment. Mol Cancer Ther; 11(12); 2693–703. ©2012 AACR.Keywords
All Related Versions
This publication has 36 references indexed in Scilit:
- The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma CellsMolecular Cancer Therapeutics, 2012
- Aurora kinase inhibitors: Progress towards the clinicInvestigational New Drugs, 2012
- P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the Aurora-B Kinase Inhibitor barasertib-hQPABMC Cancer, 2011
- Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidyMolecular Cancer, 2011
- Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutationBritish Journal of Cancer, 2010
- Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinaseProceedings of the National Academy of Sciences, 2010
- Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast CancerClinical Cancer Research, 2009
- Aurora B Kinase Regulates the Postmitotic Endoreduplication Checkpoint via Phosphorylation of the Retinoblastoma Protein at Serine 780Molecular Biology of the Cell, 2009
- CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenograftsBritish Journal of Cancer, 2009
- Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer GrowthClinical Cancer Research, 2008